News
New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...
Copycats and false advertisements are also to blame for the increased threats. Stemming from social media testimonials all ...
Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18 ...
Glucagon-like peptide-1 (GLP-1) injections like Wegovy (semaglutide) and Zepbound (tirzepatide) have revolutionized the weight-loss medication market. But oral GLP-1 pills are on the horizon and ...
Eli Lilly's GLP-1 drug Zepbound is poised to "dominate" the weight loss market, according to BMO. Weekly prescription drug data shows Zepbound has seen a surge in uptake since its recent FDA approval.
GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results